Artemisinin-based combination therapy is considered the gold standard treatment for malaria, but global demand has often outpaced production, and pricing has been volatile. With funding from the Bill & Melinda Gates Foundation, PATH and our partners set out to develop a new pharmaceutical manufacturing process to produce commercial volumes of high-quality, nonseasonal, and affordable artemisinin to supplement the plant-based supply. This poster, presented at the Bay Area World Malaria Day Symposium on April 25, 2014, presents key facts on malaria, the market for artemisinin, partner roles, and commercial production.
Corporate author(s): PATH
Publication date: April 2014
791 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- About PATH's work > Advancing technologies
- Emerging and epidemic diseases > Malaria
- For advocates and policymakers > Public-private partnerships
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA